T-Cell Differentiation pp 111-118 | Cite as
Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer
Abstract
Adoptive T cell therapy has demonstrated tremendous outcomes against treatment-refractory leukemias and solid tumor malignancies. As opposed to industry-developed drugs that are manufactured and dispensed to hospitals and/or patients, T cells are produced in academic laboratories for clinical research and are a highly personalized therapy that represents a “living drug.” The technology behind genetic modification of primary T cells has been developed and refined by a few academic medical centers. We anticipate that the exciting results generated by these efforts will lead to further investigation by other academic and industry institutions. To facilitate this adaptation we present optimized protocols for gammaretroviral production, T cell isolation, and genetic modification to create gene-targeted T cells.
Key words
T cell Chimeric antigen receptor Retroviral vector transduction Immunotherapy Adoptive cell therapyReferences
- 1.Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra225. doi: 10.1126/scitranslmed.3008226 CrossRefGoogle Scholar
- 2.Stevanovic S, Draper LM, Langhan MM et al (2015) Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 33(14):1543–1550. doi: 10.1200/JCO.2014.58.9093 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723. doi: 10.1056/NEJMoa1003466 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Topp MS, Gokbuget N, Zugmaier G et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory b-precursor acute lymphoblastic leukemia. J Clin Oncol 32(36):4134–4140. doi: 10.1200/JCO.2014.56.3247 CrossRefPubMedGoogle Scholar
- 5.Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12(4):269–281. doi: 10.1038/nri3191 CrossRefPubMedGoogle Scholar
- 6.Sadelain M, Riviere I, Brentjens R (2003) Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 3(1):35–45. doi: 10.1038/nrc971 CrossRefPubMedGoogle Scholar
- 7.Davila ML, Brentjens R, Wang X et al (2012) How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 1(9):1577–1583. doi: 10.4161/onci.22524 CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2014) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. doi: 10.1016/S0140-6736(14)61403-3 Google Scholar
- 9.Hollyman D, Stefanski J, Przybylowski M et al (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother 32(2):169–180. doi: 10.1097/CJI.0b013e318194a6e8 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Kochenderfer JN, Feldman SA, Zhao Y et al (2009) Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32(7):689–702. doi: 10.1097/CJI.0b013e3181ac6138 CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Lee J, Sadelain M, Brentjens R (2009) Retroviral transduction of murine primary T lymphocytes. Methods Mol Biol 506:83–96. doi: 10.1007/978-1-59745-409-4_7 CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Zheng Z, Chinnasamy N, Morgan RA (2012) Protein L: a novel reagent for the detection of chimeric antigen receptor (CAR) expression by flow cytometry. J Transl Med 10:29. doi: 10.1186/1479-5876-10-29 CrossRefPubMedPubMedCentralGoogle Scholar